The ALS Association is excited to announce that the request for applications for The Lawrence and Isabel Barnett Drug Development Program is now open for 2023. Letters of Intent are due Thursday, March 30, 2023, by 5 p.m. US EDT.
The Barnett Drug Development Program is open to industry and academic investigators who are developing novel therapies or repositioning treatment approaches for ALS. We are interested in funding the preclinical assessment of therapeutics for ALS that have a high probability of reaching the clinic within three years. We are especially interested in projects that involve in vivo efficacy testing in models of ALS and studies on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, target engagement or other IND-enabling work. Successful applicants will receive up to $500,000 in funding over two years.
For more details, please visit our website: https://www.als.org/research/funding-opportunities/lawrence-and-isabel-barnett-drug-development-program-2023.
If you have any questions, please reach out to email@example.com. We look forward to receiving your applications.